Kojin Therapeutics, Inc. — Form D
Kojin Therapeutics, Inc. of Boston, MA, a company, filed a Form D exempt-offering notice with the SEC on 2021-06-09. The offering totals $60.2M, of which $30.2M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-06-09
- Form: D
- Accession: 0001567619-21-011904
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $60.2M
- Amount sold: $30.2M
- Remaining: $30.0M
- Investors: 14
- Date of first sale: 2021-06-02
- Security types: equity
- Revenue range: Not Applicable
- SEC file number: 021-402309
Issuer
- Name: Kojin Therapeutics, Inc.
- CIK: 0001866204
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: One Marina Park Drive, Boston, MA, 02210
- Phone: (781) 299-7800
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Thomas J Cahill | Director | Boston, MA |
| Luba J Greenwood | Director | Boston, MA |
| Nagesh J Mahanthappa, Ph.D. | Director | Boston, MA |
| Amir Nashat, Ph.D. | Director | Boston, MA |
| Susan Langer | Executive Officer | Boston, MA |
| Amir Nashat, Ph.D. | Executive Officer | Boston, MA |
More